≡

Phosphodiesterase 9A (PDE9A)

[Edit]

High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A

Phosphodiesterase 9A (PDE9A)
CCC F655
HGNC 8795
MGI 1277179
PubMed 9624146
RGD 621035
UniProt O76083
Wiki PDE9A
Phosphodiesterase 9A(PDE9A) catalyzes the hydrolysis of cAMP and cGMP to their corresponding monophosphates. The encoded protein plays a role in signal transduction by regulating the intracellular concentration of these cyclic nucleotides. Multiple transcript variants encoding several different isoforms have been found for this gene.
Four different transcripts deriving from alternative splicing of 5-prime exons and containing the 3-prime,5-prime-cyclic nucleotide phosphodiesterase signature motif were identified. Northern blot analysis revealed several mRNA species of approximately 2.4 kb with varying expression patterns and intensities in all tissues examined except blood.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPF655Hu01 Recombinant Phosphodiesterase 9A (PDE9A) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies n/a Monoclonal Antibody to Phosphodiesterase 9A (PDE9A) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Phosphodiesterase 9A (PDE9A) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Phosphodiesterase 9A (PDE9A) CLIA Kit Customized Service Offer
n/a ELISA Kit for Phosphodiesterase 9A (PDE9A) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Phosphodiesterase 9A (PDE9A) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Phosphodiesterase 9A (PDE9A) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Phosphodiesterase 9A (PDE9A) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Phosphodiesterase 9A (PDE9A) CLIA Kit Customized Service Offer
n/a ELISA Kit for Phosphodiesterase 9A (PDE9A) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Phosphodiesterase 9A (PDE9A) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Phosphodiesterase 9A (PDE9A) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Phosphodiesterase 9A (PDE9A) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Phosphodiesterase 9A (PDE9A) CLIA Kit Customized Service Offer
n/a ELISA Kit for Phosphodiesterase 9A (PDE9A) ELISA Kit Customized Service Offer
  1. "Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase."J. Biol. Chem. 273:15559-15564(1998) [PubMed] [Europe PMC] [Abstract]
  2. "Identification and characterization of a novel cyclic nucleotide phosphodiesterase gene (PDE9A) that maps to 21q22.3: alternative splicing of mRNA transcripts, genomic structure and sequence."Hum. Genet. 103:386-392(1998) [PubMed] [Europe PMC] [Abstract]
  3. "Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene."Biochem. Biophys. Res. Commun. 301:686-692(2003) [PubMed] [Europe PMC] [Abstract]
  4. "Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants."Gene 314:15-27(2003) [PubMed] [Europe PMC] [Abstract]
  5. "Specific use of start codons and cellular localization of splice variants of human phosphodiesterase 9A gene."BMC Mol. Biol. 7:39-39(2006) [PubMed] [Europe PMC] [Abstract]
  6. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  7. "The DNA sequence of human chromosome 21." Nature 405:311-319(2000) [PubMed] [Europe PMC] [Abstract]
  8. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  9. "Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line."Mol. Pharmacol. 68:1775-1781(2005) [PubMed] [Europe PMC] [Abstract]
  10. "Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo." J. Pharmacol. Exp. Ther. 341:396-409(2012) [PubMed] [Europe PMC] [Abstract]
  11. "Phosphodiesterase 9: insights from protein structure and role in therapeutics."Life Sci. 106:1-11(2014) [PubMed] [Europe PMC] [Abstract]
  12. "Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease."Nature 519:472-476(2015) [PubMed] [Europe PMC] [Abstract]
  13. "Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding."Proc. Natl. Acad. Sci. U.S.A. 101:9624-9629(2004) [PubMed] [Europe PMC] [Abstract]
  14. "Structural basis for the catalytic mechanism of human phosphodiesterase 9."Proc. Natl. Acad. Sci. U.S.A. 105:13309-13314(2008) [PubMed] [Europe PMC] [Abstract]
  15. "Crystal structure of the human phosphodiesterase 9a catalytic domain."Submitted (FEB-2009) to the PDB data bank
  16. "Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy."J. Med. Chem. 52:7946-7949(2009) [PubMed] [Europe PMC] [Abstract]
  17. "Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis."J. Med. Chem. 53:1726-1731(2010) [PubMed] [Europe PMC] [Abstract]
  18. "Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine."PLoS ONE 6:E18092-E18092(2011) [PubMed] [Europe PMC] [Abstract]
  19. "Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design."J. Med. Chem. 55:8549-8558(2012) [PubMed] [Europe PMC] [Abstract]
  20. "Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors." J. Med. Chem. 55:9055-9068(2012) [PubMed] [Europe PMC] [Abstract]